Provided is a recombinant human antibody that binds to HCV E2 with high affinity and exhibits neutralizing activity.
Figure 1 Controls for sE2 binding to CD81−CHO or SR-B1−CHO cells.
ELISA binding of HEPC74 and HEPC98 to strain 1a154 sE2.
Mankowski, M. C., Kinchen, V. J., Wasilewski, L. N., Flyak, A. I., Ray, S. C., Crowe, J. E., & Bailey, J. R. (2018). Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences, 115(1), E82-E91.
Figure 2 HEPC74/HEPC98 neutralization follows Bliss independence.
Median effect plots comparing experimental inhibition (blue) to the inhibition predicted by either the Loewe additivity (red) or Bliss independence (orange) models. Statistically significant differences between the experimental inhibition and Loewe or Bliss predictions are indicated with red and orange asterisks, respectively. Experimental neutralization values are the means of duplicate measurements. Loewe and Bliss values are the means of four individual predictions made at each antibody concentration using data from individual NAb neutralization.
Mankowski, M. C., Kinchen, V. J., Wasilewski, L. N., Flyak, A. I., Ray, S. C., Crowe, J. E., & Bailey, J. R. (2018). Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences, 115(1), E82-E91.
Figure 3 HEPC74 and HEPC98 have distinct mechanisms of neutralization.
ELISA binding of HEPC74 or HEPC98 to strain 1a154 E1E2 alone, or in the presence serial dilutions of nonspecific human IgG, HEPC74, or HEPC98.
Mankowski, M. C., Kinchen, V. J., Wasilewski, L. N., Flyak, A. I., Ray, S. C., Crowe, J. E., & Bailey, J. R. (2018). Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences, 115(1), E82-E91.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-446 | Recombinant Human Anti-HCV E2 Antibody | FC, WB, FuncS | IgG |
HPAB-0195CQ | Human Anti-HCV E2 Protein Recombinant Antibody (HPAB-0195CQ) | ELISA, Neut, FuncS | Human IgG1 |
HPAB-0197CQ | Recombinant Human Anti-HCV E2 Antibody (HPAB-0197CQ) | ELISA, Neut | Human IgG1 |
PABC-415 | Human Anti-HCV E2 Protein Recombinant Antibody (PABC-415) | ELISA, IP, Neut, Inhib, FC | Human IgG1 |
VS-0723-XY14 | Recombinant Human Anti-HCV E1E2 Antibody (clone HC1AM) | ELISA, Neut | Human IgG |
There are currently no Customer reviews or questions for HPAB-0196CQ. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# HPAB-0196CQ, RRID: AB_3111367)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.